Abstract
In order to discover compounds that may be useful in the prevention of Alzheimer disease, a drug library was screened for drugs that could decrease amyloid β peptide (Aβ) accumulation secreted from a human CNS-derived cell line. Of the 2160 compounds subjected to a primary screen, 16, or 0.74%, reduced Ab accumulation by at least 40%. Seven of these compounds were confirmed to be effective in a secondary screen using each compound at a dose of 5 μM. Three of these seven compounds were more effective than the others at reducing Aβ levels in a tertiary screen, and led to 68 to 85% reductions in total Aβ, at the 25 μM dosage. The effects of these three drugs on secreted Aβ40, Aβ42, and sAPPα were also determined. Thus, we have identified lead compounds that may be useful for subsequent studies to determine the mechanism of action of each drug, as well as for pre-clinical studies to determine whether each of these drugs is safe and effective in vivo.
Keywords: amyloid peptide, drug screen, amyloid precursor protein
Current Alzheimer Research
Title: Drug Library Screen to Identify Compounds that Decrease Secreted Aβ from a Human Cell Line
Volume: 2 Issue: 2
Author(s): Enakshi Chakrabarti and Jonathan D. Smith
Affiliation:
Keywords: amyloid peptide, drug screen, amyloid precursor protein
Abstract: In order to discover compounds that may be useful in the prevention of Alzheimer disease, a drug library was screened for drugs that could decrease amyloid β peptide (Aβ) accumulation secreted from a human CNS-derived cell line. Of the 2160 compounds subjected to a primary screen, 16, or 0.74%, reduced Ab accumulation by at least 40%. Seven of these compounds were confirmed to be effective in a secondary screen using each compound at a dose of 5 μM. Three of these seven compounds were more effective than the others at reducing Aβ levels in a tertiary screen, and led to 68 to 85% reductions in total Aβ, at the 25 μM dosage. The effects of these three drugs on secreted Aβ40, Aβ42, and sAPPα were also determined. Thus, we have identified lead compounds that may be useful for subsequent studies to determine the mechanism of action of each drug, as well as for pre-clinical studies to determine whether each of these drugs is safe and effective in vivo.
Export Options
About this article
Cite this article as:
Chakrabarti Enakshi and Smith D. Jonathan, Drug Library Screen to Identify Compounds that Decrease Secreted Aβ from a Human Cell Line, Current Alzheimer Research 2005; 2 (2) . https://dx.doi.org/10.2174/1567205053585738
DOI https://dx.doi.org/10.2174/1567205053585738 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Complement Activation-Related Pseudoallergy Caused by Amphiphilic Drug Carriers: The Role of Lipoproteins
Current Drug Delivery Novel Insights Into the Role of MicroRNA in Lung Cancer Resistance to Treatment and Targeted Therapy
Current Cancer Drug Targets Diversity of Molecular Factors in Alzheimer’s Disease
Current Alzheimer Research Long-Term Outcome of Cardio Respiratory Exercise Performance After Surgery
Current Respiratory Medicine Reviews Adamantane – A Lead Structure for Drugs in Clinical Practice
Current Medicinal Chemistry Design, Synthesis and Biological Activity of Some 4, 5-Disubstituted-2, 4- Dihydro-3H-1, 2, 4- Triazole-3-Thione Derivatives
Central Nervous System Agents in Medicinal Chemistry Diverse Functions of γ -secretase: Releasing Signaling Fragments and Deleterious Molecules
Current Enzyme Inhibition Synthesis of New Peptide Derivatives of Galanthamine Designed for Prevention and Treatment of Alzheimer’s Disease
Protein & Peptide Letters Medicinal Chemistry of Sirtuin Inhibitors
Current Medicinal Chemistry Recent Advances in Herbal Nanomedicines for Cancer Treatment
Current Molecular Pharmacology Advances in Neuroimaging for HIV-1 Associated Neurological Dysfunction: Clues to the Diagnosis, Pathogenesis and Therapeutic Monitoring
Current HIV Research HMPAO-SPECT Can Discriminate between Patients with Subjective Cognitive Complaints with and without Cognitive Deficits and those with Mild Cognitive Impairment
Current Alzheimer Research An Overview on the Role of α -Synuclein in Experimental Models of Parkinson’s Disease from Pathogenesis to Therapeutics
CNS & Neurological Disorders - Drug Targets Applications of Solid-State Fermentation Process in Biological Detoxification of Industrial Wastes
Current Biochemical Engineering (Discontinued) Multifunctional Proteins in Tumorigenesis: Aminoacyl-tRNA Synthetases and Translational Components
Current Proteomics Vitamin D and the Metabolic Syndrome
Current Vascular Pharmacology Unusual DNA Conformations: Implications for Telomeres
Current Medicinal Chemistry - Anti-Cancer Agents Midkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System
Current Pharmaceutical Design Patient Engagement in Randomized Controlled Tai Chi Clinical Trials among the Chronically Ill
Reviews on Recent Clinical Trials Neuropharmacology of the Endocannabinoid Signaling System-Molecular Mechanisms, Biological Actions and Synaptic Plasticity
Current Neuropharmacology